Since its founding 200 years ago as a traditional drug seller and after the establishment of Amato Pharmaceutical Products along with the formulation of BORRAGINOL® about 100 years ago, Amato has thought about the life and health of patients first and foremost and has been concerned with both product quality and the information quality.
Why did Amato’s product creation not stop with the initial medicine prepared in a university hospital?
Because it was necessary to develop a product with durability to deliver it throughout Japan. With its experience as a traditional drug seller, Amato knew that the distribution of medicines could be very rough and potentially damaging. The durability of products for distribution inside hospitals and those sold in stores naturally had to be different.
Why did Amato’s development not stop with the discovery of the effective ingredients for treating disease?
This is because Amato knew that in the development of a preparation for external application, in addition to the effective ingredients, oils and other base materials, are important. The selection and development of base materials was an important factor.
Why has Amato continued to improve its products over and over?
Because Amato’s founder believed that “the only thing that could be superior to BORRAGINOL® was BORRAGINOL®,” and he gave a promise to be especially careful that this medicine was the best possible. This belief of the founder has been handed down over the years and is still kept alive by employees today.
Why does Amato have many machines for trial production?
Before production actually begins, it is important to begin by conducting many trial runs at the laboratory level. After several trials, the production increases step by step.
Why is collaborating with academic associations, including the associations for coloproctology, important for Amato?
Because in the field of pharmaceuticals, there is always a close relationship with scientific progress based on clinical trials. Professionals in universities and medical institutions gain an understanding of leading edge medical treatment under actual conditions, and the mission of pharmaceutical manufacturers is to reflect these conditions in their products.